Sorrento Therapeutics Stock - Wednesday background after bankruptcy proceedings
17.06.2026 - 14:09:14 | ad-hoc-news.de
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/17/2026, 14:07 CET. Details in the imprint.
Sorrento Therapeutics (US81803W1062) has long disappeared from active Nasdaq trading after entering Chapter 11 proceedings, and quote services now show the stock at $0.00 based on legacy SRNE data. With no fresh filings or news on Wednesday, the focus turns to the company’s background and management history.
Background and data on Sorrento Therapeutics stock
Historic articles, price data and regulatory disclosures provide context on how Sorrento Therapeutics moved from an ambitious biotech to a Chapter 11 case.
What Reuters and filings showed
Sorrento Therapeutics, Inc. once traded on Nasdaq under the ticker SRNE as a clinical-stage biopharmaceutical company targeting cancer, pain and infectious diseases. In early 2023, Sorrento and several affiliates voluntarily filed for Chapter 11 protection in the US to restructure their debt and operations, according to court documents and company statements.
The filing followed years of high research spending, limited product revenue and a volatile share price, as the group pursued antibody-drug conjugates, CAR-T therapies and COVID-related assets without reaching broad commercial scale. Public quote pages now record a legacy market capitalization in the hundreds of thousands of dollars at a stock price of $0.00, underlining how little equity value remains for common shareholders.
Background focus on Wednesday
With no new investor-relations releases, major press reports or analyst notes in the past day, Wednesday’s angle is necessarily historical and structural. The company’s archived investor materials describe an organization built around antibody discovery platforms, immuno-oncology programs and non-opioid pain therapies.
Key assets historically included antibody libraries, targeted cancer candidates and technologies designed for rapid development of biotherapeutics, reflected in pipeline charts and presentations on the investor-relations website. The Chapter 11 process aimed to maximize creditor recovery, which typically leaves common equity deeply subordinated.
The product and pipeline legacy
Before its bankruptcy path, Sorrento Therapeutics highlighted oncology and pain candidates built on its proprietary antibody technologies, including immune-oncology constructs and non-opioid pain formulations targeting persistent, difficult-to-treat indications. These programs, documented in presentations and regulatory filings, illustrate the scientific ambition that once underpinned the stock’s speculative appeal.
Where the stock trades today
The shares of Sorrento Therapeutics (US81803W1062) are now effectively inactive, with major quote services referencing a price of $0.00 for legacy SRNE listing data as of 06/17/2026, 14:07 CET in USD.
Key facts on Sorrento Therapeutics stock
- Company: Sorrento Therapeutics, Inc.
- ISIN: US81803W1062
- Ticker: SRNE (legacy Nasdaq listing)
- Venue: Nasdaq (historic)
- Price (as of 06/17/2026, 14:07 CET): 0.00 USD
- Market cap: 385,900 USD (as referenced on legacy quote data)
- Sector / Industry: Health Care / Biotechnology
- Index membership: None (stock no longer in major benchmarks)
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
